VEGF

[NPJ Regenerative Medicine] In the type 1 diabetic NOD mouse model, engineered growth factors improved both re-epithelialization and granulation tissue formation.

[Hepatic Cell News] Elevar Therapeutics, Inc. announced that the US FDA has granted rivoceranib with orphan drug designation for the treatment of HCC, the most common primary liver malignancy and is a leading cause of cancer-related death worldwide.

[Scientific Reports] Immunocytochemical analysis confirmed SULF1/SULF2 expression in endothelial cell lining of blood vessels and in developing cardiomyocytes, but not in the adult cardiomyocytes despite persisting at reduced levels in the adult endothelial cells.

[Scientific Reports] Breast cancer cells preferentially metastasize to bone. To study the bone-tumor paracrine influence, a tri-cellular 3-D vascularized breast cancer tissue model was engineered which comprised MDA-MB231, TNBCs, fibroblasts, and endothelial cells.

[Oxurion NV] Oxurion NV announced that the first patient has been dosed in Part B of its two-part, Phase II study evaluating multiple injections of THR-149 for the treatment of DME. THR-149 is being developed to potentially become the treatment of choice for the 40-50% of DME patients who respond suboptimally to anti-VEGF therapy.

[Scientific Reports] Scientists utilized cromolyn, a mast cell inhibitor with anti-inflammatory capabilities, and its fluorinated analogue F-cromolyn to study fibrosis-related protein regulation and secretion downstream of neuroinflammation and their ability to promote microglial phagocytosis and neurite outgrowth.